Amphiphilic aminoglycoside antimicrobials are an emerging class of new antibacterial agents with novel modes of action. Previous studies have shown that amphiphilic neomycin-B and kanamycin-A analogs restore potent antibacterial activity against Gram-positive neomycin-B-and kanamycin-A-resistant organisms. In this paper, we investigated the antibacterial properties of a series of amphiphilic tobramycin analogs. We prepared tobramycin-lipid conjugates, as well as tobramycin-peptide triazole conjugates, and studied their antibacterial activities against a panel of Gram-positive and Gram-negative bacterial strains, including isolates obtained from Canadian hospitals. Our results demonstrate that the antibacterial activity of amphiphilic tobramycin is greatly affected by the length and nature of the hydrophobic lipid tail, whereas the nature of the polycationic headgroup or the number of cationic charges appear to be less important. Replacement of the hydrophobic tail by a fluorinated lipid confers good activity against two Pseudomonas strains and reduces hemolytic activity. However, susceptibility studies in the presence of bovine serum albumin indicate that all amphiphilic tobramycin analogs are strongly protein-bound, leading to a typical four-to eight-fold increase in MIC.
INTRODUCTION
Polycationic antibacterials (PAs) containing multiple positively charged amino and/or guanidino functions define a structurally diverse class of antibacterials with broad-spectrum activity and different modes of action. 1 PAs can be divided into amphiphilic and non-amphiphilic PAs. Amphiphilic PAs are comprised of the naturally occurring cationic antimicrobial peptides, synthetic mimics of antimicrobial peptides, polycationic lipopeptides, lipids and surfactants, whereas non-amphiphilic PAs are represented by aminoglycoside antibiotics. The polycationic charges in PAs ensure accumulation at polyanionic microbial cell surfaces in Gramnegative and Gram-positive bacteria, respectively. 2 Several PAs including the aminoglycoside gentamicin, certain antimicrobial peptides including defensins, gramicidin S variants and others, and lipopeptides such as polymyxins transit the outer membrane by interacting at sites at which divalent cations crossbridge adjacent polyanionic polymers. This causes a destabilization of the outer membrane that is proposed to lead to self-promoted uptake of PAs and/or other extracellular molecules. 2 After transit through the outer membrane, PAs contact the anionic surface of the cytoplasmic membrane. Here, depending on the structure of the Pas, several scenarios can be envisaged. Amphiphilic PAs may insert themselves into the cytoplasmic membrane, thereby either disrupting the physical integrity of the bilayer, via membrane thinning, transient poration and/or disruption of the barrier function, or translocation across the membrane and acting on internal targets. 2 Non-amphiphilic PAs like aminoglycosides must cross the membrane to bind to ribosomal RNA.
Our previous work has shown that amphiphilic aminoglycosides such as neomycin, kanamycin and neamine analogs restore potent antibacterial activities against certain Gram-positive and Gramnegative organisms, including multidrug-resistant isolates obtained from Canadian hospitals. [3] [4] [5] [6] [7] For instance, when compared with their parent aminoglycosides, both neomycin-B-based hexacationic C 16 -lipid 7 or kanamycin-A-based tetracationic lipid C 16 -lipid 6 ( Figure 1 ) displayed 64-to 32-fold enhanced antibacterial activity against methicillin-resistant Staphylococcus aureus, whereas a 4-to 8-fold decrease in MIC was observed against two Pseudomonas aeruginosa strains. 4 Similarly, conjugation of neomycin-B and kanamycin-A to an ultrashort hydrophobic dipeptide led to a 16-fold lower MIC against methicillin-resistant Staphylococcus aureus and a 4-to 32-fold lower MIC against Pseudomonas aeruginosa strains. The physicochemical similarities between amphiphilic aminoglycosides and amphiphilic PAs suggest a membranolytic mode of action. 8, 9 This hypothesis is supported by (a) the observed concentration-dependent hemolytic activity of 6 and 7; 5 and (b) the requirement for a strongly hydrophobic lipid segment to induce potent antibacterial activity 4 and a recent study of C5''-modified neomycin-B-based polycationic lipids that have demonstrated that polycationic neomycin-lipid conjugates synergistically enhance the antibacterial activity of antibiotics interacting with intracellular targets such as amikacin and neomycin. 9 To further explore the structural activity relationships in this class of polycationic amphiphiles, we now became interested in studying the antibacterial effects of amphiphilic tobramycin analogs. To the best of our knowledge, this is the first study on amphiphilic tobramycin analogs. We were particularly interested in exploring how the nature of the hydrophobic lipid tail affects antibacterial activity in amphiphilic tobramycin analogs, and how the activity of amphiphilic tobramycin compares with amphiphilic kanamycin-A and neomycin-B.
MATERIALS AND METHODS

Antibacterial agents
Two classes of amphiphilic tobramycin analogs were prepared. The first class are tobramycin-based polycationic lipids 2, 3, 4 and 5 ( Figure 1 ), whereas the second class are tobramycin-based triazole conjugates 9 and 10 ( Figure 2 ). We also studied the corresponding kanamycin-A-and neomycin-B-based polycationic lipids 6, 7 and 8, together with their triazole conjugates 11 and 12. Tobramycin, kanamycin, neomycin and 6'-azidodeoxy-tobramycin 1 served as reference compounds. All synthetic compounds were prepared following our previously established methodology. 3, 4, 6 The identity of all amphiphilic tobramycin, neomycin-B and kanamycin-A analogs were assessed by EI-MS, 1 H NMR, and 13 C NMR (see Supplementary Information). Tobramycin, kanamycin-A and neomycin-B were purchased from Sigma Aldrich Canada Ltd (Oakville, Ontario, Canada). 10 
Bacterial strains
MIC determination
Antibacterial activity against Gram-positive and Gram-negative organisms was assessed via broth macrodilution using Clinical and Laboratory Standards Institute (CLSI) methodology. 10 Stock solutions of amphiphilic aminoglycosides were prepared to a concentration of 512 mg ml À1 in water. Organisms were subcultured and isolated on blood agar, suspended in 3 ml of Mueller-Hinton broth at the turbidity of a 0.5 M McFarland standard, and diluted to approximately 10 5 CFU ml À1 before introduction into tubes containing serially diluted lipopeptide antibiotic in Mueller-Hinton broth. The turbidity resulting from lipopeptide solution in broth required the creation of control tubes lacking microbes serving as turbidity controls. All tubes were incubated overnight for 16-20 h at 37 1C. In some cases, the MIC study was performed in the presence of 4% bovine serum albumin to study protein binding.
Hemolytic activity
In-vitro toxicity was determined using a sheep red blood cell hemolytic assay as previously described. 11 Pilot experiments have shown that both human and sheep erythrocytes respond similarly in this hemolytic assay (data not shown). In brief, the erythrocytes were washed and resuspended in Tris-buffered saline. The cell suspension will be combined with varying concentrations (low to very high) of kanamycin, neomycin, tobramycin and amphiphilic aminoglycosides. The samples were centrifuged and the absorbance of the supernatants was measured at 540 nm. Tris-buffered saline and Triton X were used as negative and positive controls, respectively. The toxicity was assessed by percent hemolysis. 11 
RESULTS AND DISCUSSION
In this study, a total of seven amphiphilic and non-amphiphilic tobramycin-based analogs as well as certain corresponding amphiphilic kanamycin and neomycin analogs were synthesized. Our curiosity was driven by previous observations from our laboratory 3 Figure 2 Structures of amphiphilic tobramycin-, kanamycin-A-and neomycin-B-based triazole peptide conjugates.
Antibacterial activity of amphiphilic tobramycin R Dhondikubeer et al and others, 7, 8 which have shown that conversion of the nonamphiphilic aminoglycosides neomycin-B and kanamycin-A into amphiphilic aminoglycosides enhances antibacterial activity against aminoglycoside-resistant and multidrug-resistant Gram-positive bacteria. [3] [4] [5] The compounds were selected to explore how the nature of the cationic aminoglycoside-based headgroup, the number of cationic charges and the nature of the hydrophobic lipid tail affects antibacterial activity in this class of compounds. At first, we explored how the nature of the hydrophobic tail affects the antibacterial activity in tobramycin-based amphiphiles. The single primary hydroxy group of tobramycin was converted into an amino function and conjugated to various fatty acid-based lipid tails. We selected a C 16 -and fluorinated C 12 -lipid tails. We also explored aromatic tails and shorter C 6 lipid tails in the form of carbamates. Our results clearly demonstrate that amphiphilicity is critical for antibacterial activity as tobramycin-C 6 lipid 2 and tobramycin-phenylcarbamate 3 are nearly devoid of antibacterial activity (Table 1 ). In contrast, tobramycin-C 16 -lipid 4 displays good antibacterial activity against most Gram-positive (MIC p4-8 mg ml À1 ), and some Gram-negative organisms including E. coli and one Pseudomonas aeruginosa strain. The potent activity of 4 (MIC o0.25) against methicillin-resistant Staphylococcus epidermidis is especially noteworthy. Replacement of the C 16 -lipid in 4 by a partially fluorinated lipid tail with comparable hydrophobicity 12 as in compound 5 does not improve the antibacterial activity and generally leads to an expected two-fold reduction in MIC when the increase in MW is considered. It is noteworthy that compound 5 displays good antibacterial activity (MIC ¼ 16) against two Pseudomonas aeruginosa strains. Next, we studied how the nature of the polycationic headgroup and the number of polycationic charges affects the antibacterial activity. Besides the pentacationic tobramycin-based headgroup, we selected the tetracationic kanamycin-A and the hexacationic neomycin-B headgroups. With the exception of methicillin-resistant Staphylococcus epidermidis and Pseudomonas aeruginosa, conjugation of the three differently charged headgroups to a C 16 hydrophobic tail results in almost identical antibacterial activity for compounds 4, 6 and 7, indicating that the nature of the polycationic headgroup is not critical for the antibacterial activity. Interestingly, a four-to eight-fold reduction in MIC is observed against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus epidermidis when the polycationic headgroup of neomycin and kanamycin is replaced by tobramycin, indicating that the pentacationic tobramycin-based headgroup appears to be optimal for both organisms. In addition, as observed for tobramycin analog We also studied how substitution of the fatty acid-based lipid tail by a hydrophobic dipeptide sequence affects antibacterial activity in amphiphilic tobramycin analog 10 ( Figure 2 ). For comparison with previously synthesized amphiphilic peptides 11 and 12, we selected the hydrophobic Fmoc-protected dipeptide sequence consisting of triazol-modified glycine and tryptophan. 6 A previous study has shown that the hydrophobic Fmoc-protecting group in this dipeptide sequence improves antibacterial activity. 6 We also prepared the less amphiphilic tobramycin-based triazole analog 9 as a reference compound. Our results demonstrate that replacement of the lipid tail in 4 by a hydrophobic peptide sequence in compound 10 results in a two-to four-fold increase in MIC against most Grampositive strains, whereas the same or a two-fold increased MIC was observed against most Gram-negative organisms. The same trend is observed with amphiphilic kanamycin-A peptide triazole conjugate 11 and neomycin-B triazole conjugate 12.
To further explore the potential toxicity of amphiphilic tobramycin analogs, we studied their hemolytic activities at two different concentrations (Table 1 ). Our results demonstrate that amphiphilic tobramycin analogs with highly hydrophobic tails such as compounds 4 and 10 show concentration-dependent hemolytic activity, as it is observed for other amphiphilic aminoglycoside analogs such as compounds 6 and 7. Generally, it appears that a hydrophobic peptide tail results in reduced hemolytic activity when compared with a C 16 lipid tail for all three types of aminoglycosides. Moreover, replacement of the hydrophobic lipid tail in both compounds 4 and 7 by a fluorinated lipid tail as in compounds 5 and 8 significantly reduces the hemolytic activity, suggesting that fluorinated lipid tails may reduce cytotoxicity. However, both amphiphilic tobramycin-lipid conjugates experience a typical four-to eight-fold reduction in antibacterial activity against most organisms in the presence of 4% bovine serum albumin, indicating that these compounds bind strongly to proteins. A similar antibacterial deactivation has previously been observed with other classical cationic amphiphiles such as benzethonium chloride. 13 In summary, we have established that the antibacterial activity of amphiphilic tobramycin analogs is greatly affected by the length and nature of the lipid tail. In contrast, the nature of the polycationic headgroup or the number of the cationic charges appear to be less important for induction of antibacterial activity. The most potent antibacterial is tobramycin-C 16 lipid 4, which displays good Grampositive activity, but reduced Gram-negative activity. Replacement of the C 16 lipid tail by a fluorinated lipid tail confers good activity against two Pseudomonas aeruginosa strains and reduces hemolytic activity. However, susceptibility studies in the presence of bovine serum albumin indicate that all amphiphilic tobramycin analogs are strongly protein-bound, leading to a typical four-to eight-fold increase in MIC.
